CXCL12 conferred the resistance to adriamycin on CML cells by augmenting their CXCR4 expression and CXCR4 siRNA treatment can partially reduce adriamycin resistance [79]. This evidence concerns the gene CXCR4 and chronic myelogenous leukemia, BCR-ABL1 positive.